Enrolling by invitationPhase 2NCT05145010
Extension Study of Infigratinib in Children With Achondroplasia (ACH)
Studying Achondroplasia
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- QED Therapeutics, a BridgeBio company
- Principal Investigator
- QED Therapeutics SVP, Clinical DevelopmentQED Therapeutics
- Intervention
- Infigratinib(drug)
- Enrollment
- 300 enrolled
- Eligibility
- 3-18 years · All sexes
- Timeline
- 2021 – 2032
Study locations (30)
- USCF Benioff Children's Hospital, Oakland, Oakland, California, United States
- Children's Hospital Colorado, Aurora, Colorado, United States
- Nemours Alfred I. Dupont Hospital for Children, Wilmington, Delaware, United States
- Johns Hopkins University, Baltimore, Maryland, United States
- University of Missouri, Columbia, Missouri, United States
- Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio, United States
- Vanderbilt University Medical Center, Nashville, Tennessee, United States
- University Hospital and UW Health Clinics, Madison, Wisconsin, United States
- Hospital de Pediatría SAMIC Prof. Dr. Juan P. Garrahan, Ciudad Autonoma Buenos Aires, Buenos Aires, Argentina
- Murdoch Children's Hospital, Parkville, Victoria, Australia
- Stollery Children's Hospital, Edmonton, Alberta, Canada
- Children's Hospital - London Health Sciences Centre, London, Ontario, Canada
- Children's Hospital of Eastern Ontario, Ottawa, Ontario, Canada
- Centre Hospitalier Universitaire Sainte-Justine, Montreal, Quebec, Canada
- Hopital Femme Mere Enfant, Lyon, France
- +15 more locations on ClinicalTrials.gov
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT05145010 on ClinicalTrials.govOther trials for Achondroplasia
Additional recruiting or active studies for the same condition.
- RECRUITINGNCT07388966Prospective Longitudinal Monocentric Study to Measure Limb Movement in Patients With FGFR3-related Skeletal DysplasiaSYSNAV
- RECRUITINGPHASE2, PHASE3NCT07441876A Phase 2/3 Study to Evaluate the Efficacy and Safety of BMN 333 Versus Vosoritide in Children With AchondroplasiaBioMarin Pharmaceutical
- RECRUITINGPHASE2NCT07169279Interventional Study of Infigratinib in Children < 3 Years Old With Achondroplasia (ACH)QED Therapeutics, a BridgeBio company
- RECRUITINGNCT07301463A Study in Children With AchondroplasiaAbbisko Therapeutics Co, Ltd
- RECRUITINGPHASE2NCT06842355A Study of TYRA-300 in Children With Achondroplasia: BEACH301Tyra Biosciences, Inc
- RECRUITINGPHASE2NCT06732895A Clinical Trial to Evaluate Efficacy and Safety of Navepegritide in Adolescents (12 - 18 Years of Age) With Achondroplasia.Ascendis Pharma A/S
- RECRUITINGPHASE3NCT06926491Evaluate the Efficacy and Safety of KK8398 in Patients With Achondroplasia（AOBA Study）Kyowa Kirin Co., Ltd.
- ACTIVE NOT RECRUITINGPHASE2NCT06433557A Phase 2 Clinical Trial to Evaluate Efficacy, Safety, and Tolerability of Navepegritide in Combination With Lonapegsomatropin in Children With AchondroplasiaAscendis Pharma Growth Disorders A/S